TWD 179.0
(-1.65%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 522.44 Million TWD | 0.61% |
2022 | 519.28 Million TWD | 19.97% |
2021 | 432.83 Million TWD | 11.42% |
2020 | 388.47 Million TWD | 52.12% |
2019 | 255.37 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 155.93 Million TWD | 4.76% |
2024 Q1 | 148.84 Million TWD | 4.99% |
2023 Q4 | 141.76 Million TWD | 0.13% |
2023 FY | 522.44 Million TWD | 0.61% |
2023 Q3 | 141.58 Million TWD | 15.53% |
2023 Q2 | 122.55 Million TWD | 5.15% |
2023 Q1 | 116.54 Million TWD | -6.31% |
2022 FY | 519.28 Million TWD | 19.97% |
2022 Q4 | 124.4 Million TWD | 0.0% |
2021 FY | 432.83 Million TWD | 11.42% |
2020 FY | 388.47 Million TWD | 52.12% |
2019 FY | 255.37 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 495.65 Million TWD | -5.406% |
Maxigen Biotech Inc. | 274.24 Million TWD | -90.505% |
SciVision Biotech Inc. | 312.85 Million TWD | -66.993% |
Bionime Corporation | 673.63 Million TWD | 22.443% |
Pegavision Corporation | 1.68 Billion TWD | 69.034% |